Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. The company maintains a net debt-free balance sheet with cash and cash equivalents of INR379.3 million as of the latest quarter. The Board recently approved a bonus issue in the ratio of 1:1, indicating strong financial position and confidence in future growth. Capex plans (INR80-100 crores) for the current and next year are funded internally, including investments in new facilities, biologics CRDMO setup, and equipment. No indication of external equity or debt raising was

Any current/future capex/capital investment/strategic investment?

FY '26 planned capex: INR 80-100 crores, with INR 26 crores already spent in Q1 FY '26. Approximately 30% of FY '26 capex is earmarked for biologics contract research and development services setup. Remaining capex aims at purchasing new equipment and replacing existing equipment. Past capex majorly spent on new facility construction (over INR 60 crores in previous year). Investments also focused on digitizing and automating laboratory processes. New facility infrastructure created to support organic growth for the next 5 years. Ongoing capex includes final payments on new building and expandi

Future growth expectations in sales/revenue/volumes?

Vimta Labs expects healthy growth, targeting a 15% to 20% CAGR, which is about double the industry growth rate. The company aims to double its turnover within the next 3 years based on current and planned capex. Growth drivers include pharmaceutical services (preclinical, clinical research, cGMP analytical), electrical and electronics testing (a sunrise industry), and biologics contract research and development services expected to commercialize from Q1 FY 2027. Export revenue, mainly from pharmaceutical services, is growing strongly and expected to sustain. Expansion in laboratory infrastruct

Future growth expectations in earnings/operating earnings/profits/EPS?

Vimta Labs aims to achieve an annual revenue run rate of INR 120-125 crores by end of the current year, targeting INR 500 crore annually. EBITDA margins are currently strong at around 35%, but a potential 1-2% compression is expected in the near term due to new facility maintenance and rising HR costs. The company is optimistic about doubling turnover in 3 years, driven by organic growth across pharma services, biologics CRDMO, and expanding electronic/electrical testing. Export revenues, mainly pharma-related, are growing and expected to be sustainable. Continuous investments in automation, d

Current/ Expected Orderbook/ Pending Orders?

The clinical trial pipeline is described as "quite encouraging" with a decent number of inquiries received in the last quarter. A couple of clinical trial projects are in the final stages of conversion, with others also looking promising. The company is focusing on building a track record in clinical trials, which is a new area for them. No specific numeric order book or pending order values are disclosed in the transcript. Overall demand across sectors including pharma, food, and electronics is positive. Management is striving to reach quarterly revenue run rates of INR 120-125 crores. Growth

IN US

Sale is live|00:00:00left today

Vimta Labs LtdQ2 FY25Healthcare Services

Vimta Labs Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹598P/E: 25.6Market Cap: ₹2.0K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Vimta Labs expects healthy growth, targeting a 15% to 20% CAGR, which is about double the industry growth rate.
→The company aims to double its turnover within the next 3 years based on current and planned capex.
→Growth drivers include pharmaceutical services (preclinical, clinical research, cGMP analytical), electrical and electronics testing (a sunrise industry), and biologics contract research and development services expected to commercialize from Q1 FY 2027.
→Export revenue, mainly from pharmaceutical services, is growing strongly and expected to sustain.
→Expansion in laboratory infrastructure will support organic growth for the next 5 years without need for additional space.
→New areas like defense and telecom in electronics testing and biologics CRDMO offer significant growth opportunities.
→Government push for indigenous manufacturing and increasing regulations will further aid growth.

Margin guidance

Category 4

→Vimta Labs aims to achieve an annual revenue run rate of INR 120-125 crores by end of the current year, targeting INR 500 crore annually.
→EBITDA margins are currently strong at around 35%, but a potential 1-2% compression is expected in the near term due to new facility maintenance and rising HR costs.
→The company is optimistic about doubling turnover in 3 years, driven by organic growth across pharma services, biologics CRDMO, and expanding electronic/electrical testing.
→Export revenues, mainly pharma-related, are growing and expected to be sustainable.
→Continuous investments in automation, digitization, and infrastructure expansion support efficiency and future growth.
→Growth drivers include pharmaceutical preclinical/clinical services, biologics CRDMO commercialization (from FY 27), and rising demand in defense/electronics testing sectors.
→Overall, earnings and profitability are expected to grow but with slight margin pressure in the short-to-medium term.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
→The company maintains a net debt-free balance sheet with cash and cash equivalents of INR379.3 million as of the latest quarter.
→The Board recently approved a bonus issue in the ratio of 1:1, indicating strong financial position and confidence in future growth.
→Capex plans (INR80-100 crores) for the current and next year are funded internally, including investments in new facilities, biologics CRDMO setup, and equipment.
→No indication of external equity or debt raising was disclosed during the Q&A or management commentary.

Order book

→The clinical trial pipeline is described as "quite encouraging" with a decent number of inquiries received in the last quarter.
→A couple of clinical trial projects are in the final stages of conversion, with others also looking promising.
→The company is focusing on building a track record in clinical trials, which is a new area for them.
→No specific numeric order book or pending order values are disclosed in the transcript.
→Overall demand across sectors including pharma, food, and electronics is positive.
→Management is striving to reach quarterly revenue run rates of INR 120-125 crores.
→Growth is expected organically using the expanded capacity built for the next half a decade.

Capex plans

Yes

→FY '26 planned capex: INR 80-100 crores, with INR 26 crores already spent in Q1 FY '26.
→Approximately 30% of FY '26 capex is earmarked for biologics contract research and development services setup.
→Remaining capex aims at purchasing new equipment and replacing existing equipment.
→Past capex majorly spent on new facility construction (over INR 60 crores in previous year).
→Investments also focused on digitizing and automating laboratory processes.
→New facility infrastructure created to support organic growth for the next 5 years.
→Ongoing capex includes final payments on new building and expanding capacities across business units.
→No immediate mention of new strategic investments beyond the biologics CRDMO setup and digitization efforts.

How does Vimta Labs Ltd rank vs peers in Healthcare Services?

Pro feature

1Vimta Labs Ltd

Rev 3Mar 4

See full Healthcare Services sector rankings

Want more stocks like Vimta Labs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio